Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02568501 · ClinicalTrials.gov registry record · Phase 3

Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults

A Phase 3 study, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 3
Development phase
90
Enrollment target

NCT02568501: Completed Phase 3 study, sponsored by University of Pennsylvania.

NCT02568501 is a Phase 3 study that has completed, run by University of Pennsylvania. The registered enrollment target is 90 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02568501, a Phase 3 study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 3
Development phase
90 participants
Enrollment target

Study Summary

In this study the investigators will compare a novel approach using daily financial incentives and a tiered sponsor network to motivate adolescents and young adults with type 1 diabetes to improve glycemic control.

Primary Outcome

Change in HbA1c from baseline to 3 months

Interventions

  • BEHAVIORAL Financial incentive
  • BEHAVIORAL Daily feedback

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2016-01
Est. Completion 2016-11
Phase Phase 3
University of Pennsylvania

1,423 total trials

What the finished NCT02568501 record still lists

NCT02568501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).

The record links to 0 conditions, and to 2 interventions - of which Financial incentive is the first listed.

NCT02568501 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02568501 about?

NCT02568501 is a clinical study titled "Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults". In this study the investigators will compare a novel approach using daily financial incentives and a tiered sponsor network to motivate adolescents and young adults with type 1 diabetes to improve glycemic control.

What is the current status of trial NCT02568501?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2016-01. Estimated completion is 2016-11.

What interventions are being tested in trial NCT02568501?

The interventions under investigation include: Financial incentive (BEHAVIORAL), Daily feedback (BEHAVIORAL).

Who is sponsoring clinical trial NCT02568501?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02568501's enrollment target sits among peer trials

90 1724th of 2000 higher than 263 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02568501, the US trial registry maintained by the National Library of Medicine. NCT02568501 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.